Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Gen 2 Travoprost Intracameral Implant
Gen 2 Travoprost Intracameral · 2 trials · 1 indication
Change from baseline in diurnal IOP in the study eye at 8am and 10am at each of Day 11, Week 6, and Month 3 visits
| Arm | Type | Description |
|---|---|---|
| Cohort X Gen 2 Travoprost Intracameral Implant Arm | EXPERIMENTAL | Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and undergo an exchange procedure at month 12 and be followed for an additional 12 months |
| Cohort X Timolol Arm | ACTIVE_COMPARATOR | Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will administer timolol 0.5% eye drops BID (plus sham procedure) in the study eye and undergo a sham exchange procedure at month 12 and be followed for an additional 12 months |
| Cohort Y Gen 2 Travoprost Intracameral Implant Arm | ACTIVE_COMPARATOR | Randomized, double-masked, active-controlled, Phase 3 portion of the trial, subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and undergo an exchange procedure at month 24 and be followed for an additional 12 months |
| Cohort Y Timolol Arm | ACTIVE_COMPARATOR | Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will receive timolol 0.5% eye drops BID (plus sham procedure) in the study eye and undergo a sham exchange procedure at month 24 and be followed for an additional 12 months |
| Cohort Z Gen 2 Travoprost Intracameral Implant Arm | EXPERIMENTAL | Randomized, double-masked, active-controlled, Phase 3 portion of the trial, subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and undergo an exchange procedure at month 36 and be followed for an additional 12 months |
| Cohort Z Timolol Arm | ACTIVE_COMPARATOR | Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will administer timolol 0.5% eye drops BID (plus sham procedure) in the study eye and undergo an sham exchange procedure at month 36 and be followed for an additional 12 months |
| Period 1 (Cohort A) | EXPERIMENTAL | Single-arm, open-label portion of Phase 2; subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and be followed for 36 months |
| Period 2 (Cohort B) Gen 2 Travoprost Intracameral Implant Arm | EXPERIMENTAL | Randomized, double-masked, active-controlled Phase 2 portion of the trial; subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and be followed for 36 months |
| Period 2 (Cohort B) Timolol Arm | ACTIVE_COMPARATOR | Randomized, double-masked, active-controlled, Phase 2 portion of the trial; subjects will administer timolol 0.5% eye drops BID (plus sham procedure) in the study eye and be followed for 36 months |
| Name | Type | Description |
|---|---|---|
| Gen 2 Travoprost Intracameral Implant | DRUG | Travoprost |
| Timolol eye drops 0.5% | DRUG | Timolol 0.5% |
| Sham Procedure | PROCEDURE | Sham implant administration |
| placebo eye drops | OTHER | Artificial Tears |
Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
Gen 2 Travoprost Intracameral is an investigational small molecule implant being developed for glaucoma. It is designed to deliver travoprost inside the eye and is given as an intracameral implant. Glaukos Corporation is developing it, and it is currently in Phase 3 clinical development.
Gen 2 Travoprost Intracameral is being developed for the treatment of glaucoma. Both of its clinical trials enroll adults with glaucoma in the United States. It is investigational and has not been approved for commercial use.
Gen 2 Travoprost Intracameral targets the FP receptor, the prostaglandin F receptor. Travoprost is a prostaglandin analog, and activity at the FP receptor is the mechanism by which this class of small molecules acts in glaucoma therapy. The implant delivers the drug intracamerally.
Glaukos Corporation, which trades on the New York Stock Exchange under the ticker GKOS, is developing Gen 2 Travoprost Intracameral. The company is running the clinical program for the implant in glaucoma.
Gen 2 Travoprost Intracameral is in Phase 3 development. It is investigational and has not been approved by the FDA. The program includes two active, recruiting trials, one Phase 3 and one Phase 2, with a combined planned enrollment of 620 participants.
Gen 2 Travoprost Intracameral is being studied in two recruiting trials: NCT07495852, a Phase 3 trial of the second generation travoprost intracameral implant with 510 planned participants, and NCT07075718, a Phase 2 trial with 110 planned participants. Both enroll adults with glaucoma in the United States.
Yes. Gen 2 Travoprost Intracameral and Gen 2 Travoprost Intracameral Implant refer to the same investigational glaucoma product from Glaukos Corporation. The implant name reflects the intracameral delivery format used in its Phase 3 and Phase 2 trials.